Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.93M | 1.72M | 2.26M | 2.36M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.93M | 1.72M | 2.26M | 2.36M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.93M | 1.72M | 2.26M | 2.36M | -- |
| SG&A Expenses | 8.52M | 6.52M | 6.31M | 5.82M | 6.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.78M | 15.35M | 17.07M | 17.03M | 16.54M |
| Operating Income | -13.85M | -13.63M | -14.80M | -14.67M | -16.54M |
| Income Before Tax | -13.27M | -13.09M | -14.02M | -13.93M | -17.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.27M | -13.09M | -14.02M | -13.93M | -17.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.27M | -13.09M | -14.02M | -13.93M | -17.20M |
| EBIT | -13.85M | -13.63M | -14.80M | -14.67M | -16.54M |
| EBITDA | -13.35M | -13.25M | -14.42M | -14.23M | -16.10M |
| EPS Basic | -0.18 | -0.20 | -0.22 | -0.32 | -0.62 |
| Normalized Basic EPS | -0.11 | -0.13 | -0.14 | -0.20 | -0.36 |
| EPS Diluted | -0.18 | -0.20 | -0.22 | -0.32 | -0.62 |
| Normalized Diluted EPS | -0.11 | -0.13 | -0.14 | -0.20 | -0.36 |
| Average Basic Shares Outstanding | 74.70M | 64.68M | 63.47M | 43.95M | 27.91M |
| Average Diluted Shares Outstanding | 74.70M | 64.68M | 63.47M | 43.95M | 27.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |